Vivek Ramaswamy's Nuclear Startup Raises at $1.9 Billion Value

Vivek Ramaswamy's nuclear startup has raised funding at a $1.9 billion valuation, Bloomberg reports, marking one of the most valuable private financings to date for a venture tied to the entrepreneur and political figure.

The round, reported by Bloomberg, values the company at just under $2 billion. Bloomberg identified the business as a nuclear startup founded by Ramaswamy, the biotech investor and former Republican presidential candidate who has built his career on large, conviction-driven bets across industries.

What do we know about the deal?

The confirmed facts from Bloomberg's report are narrow but significant:

• The startup has completed a fundraising round.
• Bloomberg values the company at $1.9 billion.
• The founder is Vivek Ramaswamy.

Bloomberg's headline, "Vivek Ramaswamy's Nuclear Startup Raises at $1.9 Billion Value," is the authoritative summary of the transaction at this stage. The outlet has not yet published the investor list, the amount of primary capital raised, or the round's stage in its widely syndicated reporting on the deal.

Why does a nuclear startup matter now?

Nuclear energy has become one of the most heavily funded corners of climate and infrastructure technology. Startups in the sector are pursuing next-generation reactor designs, fuel cycles, and related infrastructure, and investors have pushed valuations sharply higher as governments and large energy consumers seek firm, low-carbon power.

A $1.9 billion valuation places Ramaswamy's venture among the upper tier of private nuclear companies, a category where multi-billion-dollar private marks were rare only a few years ago.

Who is Vivek Ramaswamy?

Ramaswamy made his fortune in biotech as founder of Roivant Sciences, the drug-development holding company he took public in 2021. He later ran for the 2024 Republican presidential nomination before exiting the race and moving into government-aligned roles. His entry into nuclear energy extends a pattern of taking positions in industries where policy, capital markets, and technology intersect.

For Ramaswamy personally, the round represents another founder mark near the $2 billion level, built outside his original biotech base.

What comes next?

The valuation sets the benchmark for any future financing and for how investors will judge the startup's technical and commercial progress. Bloomberg's reporting will be the source to watch for the round's backers, the capital raised, and the company's specific nuclear technology focus.